Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.

By The RX Index Editorial TeamLast verified: May 28, 2026Sources: CMS, KFF, AHA, Medicare.gov, FDA, peer-reviewed trials

What Happens After the Medicare GLP-1 Bridge Ends?

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

Here’s what happens after the Medicare GLP-1 Bridge ends: on December 31, 2027, the program’s $50-a-month price for Wegovy, Zepbound, and Foundayo goes away — and right now there is no guaranteed Medicare price to replace it. CMS has planned a bigger follow-up program called BALANCE, but it’s already been pushed back once and may not reach Medicare drug plans until 2028 — if it arrives at all.

But here’s the part nobody puts in the headline. If you take your GLP-1 for a health problem Medicare already covers — like obstructive sleep apnea, heart disease, or type 2 diabetes — that coverage isn’t tied to the Bridge’s 2027 deadline. It’s a completely separate door. And it may already be open for you.

So breathe. You have time, and you have options. Below, we lay out exactly what’s locked in, what’s still up in the air, and the smartest move to make before the deadline gets close — including a quick way to find out which coverage path is actually yours.

The 30-second version: confirmed vs. not confirmed yet

We built this page around one simple idea: separate what CMS has actually decided from what’s still a maybe. Mixing those two up is how people panic — or worse, how they assume coverage will be there in 2028 and get a nasty surprise.

What’s confirmed right now

✓The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027. (CMS)
✓Eligible members pay $50 a month for a covered drug — at any dose. (CMS)
✓Covered weight-loss drugs: Wegovy (shot or pill), Zepbound KwikPen, and Foundayo. (CMS)
✓The Bridge is temporary by design. It was built to be a short bridge, not permanent coverage. (CMS)

What’s NOT confirmed yet

?Whether Medicare will keep covering these drugs for weight loss after 2027. BALANCE is planned but delayed. (KFF, AHA)
?Whether your specific plan will offer a path in 2028.
?Whether the $50 price continues in any form.

What to do about it

Use 2026 and 2027 to lock in the most durable path you can. For most people, that means finding out whether your GLP-1 qualifies under a condition Medicare already covers — because that path isn’t on the Bridge’s clock. We’ll walk you through it.

The uncomfortable truth — and the reason you can trust the rest of this page: Nobody can honestly promise you that Medicare will still cover GLP-1s for weight loss on January 1, 2028. Anyone who says otherwise is guessing. CMS extended the Bridge because the long-term program wasn’t ready — too few insurers signed on. That’s not a reason to panic. It’s a reason to plan now, while you have time and choices, instead of scrambling at your last refill.

The Medicare GLP-1 Bridge Endgame Matrix

This is the table we wish existed when we started researching. To build it, we had to open the CMS program page, KFF’s policy analysis, Medicare.gov, the FDA, three manufacturer pricing pages, and a couple of clinical trials. You get it in one place. Find the row that sounds like you.

Your situation around the Bridge end date	What’s confirmed	What’s uncertain	Your smartest move
You're on the Bridge for weight loss only	The $50 price ends Dec. 31, 2027 (CMS)	Whether any Medicare price replaces it in 2028 (KFF)	Ask your doctor now if you might also qualify under a covered condition. Build a cash-pay backup before late 2027.
You also have sleep apnea, heart disease, or diabetes	Medicare can cover GLP-1s for these uses through normal Part D — separate from the Bridge (CMS)	Your plan's exact copay, prior-approval rules, and drug list	Get the diagnosis documented and ask your plan to cover the drug for that reason. This is the durable path.
You're hoping BALANCE saves the day in 2028	CMS wants to launch it; talks with Lilly and Novo are done (CMS)	Whether it actually reaches Medicare drug plans, and when (KFF, AHA)	Treat 2028 as a maybe. Have a real plan that doesn't depend on it.
You'll pay cash if you have to	Real cash prices exist: about $149–$449/month depending on the drug (Lilly, NovoCare, Ro)	Prices and offers change; Medicare members can't use copay cards	Compare cash options — and note that buying direct often beats a telehealth membership.
You're a caregiver for a parent	The end date is a hard benefits deadline	Whether the current plan and drug carry into 2028	Gather records, mark Open Enrollment on the calendar, and set a 'most we can afford' number.
You might have to stop the drug	Many people regain weight after stopping (STEP 1 extension; SURMOUNT-4, JAMA)	How much you would regain	Talk to your doctor about a maintenance plan before the coverage changes, not after.

Get your free, personalized GLP-1 action plan →

Two minutes. See your most realistic path before the deadline gets close. No cost, no pressure.

What happens after the Medicare GLP-1 Bridge ends?

After the Medicare GLP-1 Bridge ends on December 31, 2027, your coverage does not automatically continue under today’s confirmed rules. What happens next depends on whether CMS launches a replacement, whether your drug qualifies under a separate Medicare-covered condition, or whether you move to a cash-pay plan. The most reliable outcome is the one tied to a covered medical condition, because that path isn’t on the Bridge’s clock.

There are really four ways this can go. Let’s be honest about each.

CMS extends the Bridge again.

It already happened once — the program was first set to end in 2026 and got pushed to 2027. Another extension is possible, but you can't bank on it.

CMS launches BALANCE for Medicare drug plans.

This is the official plan. But the Medicare piece was delayed, and policy experts say it's genuinely uncertain whether it lands in 2028. (KFF, AHA)

You move to standard Part D because you qualify another way.

If your GLP-1 is for sleep apnea, heart disease, or diabetes, Medicare's normal drug coverage may apply — and it isn't tied to the Bridge's end date. (CMS) For a lot of readers, this is the answer.

You lose the $50 price and need a backup.

That could mean a covered-condition request, an appeal, manufacturer cash pricing, or a telehealth plan. We'll show you the real numbers so there are no surprises.

What you should NOT assume

✗Don't assume the Bridge becomes permanent.
✗Don't assume your plan will cover the same drug in 2028.
✗Don't assume the $50 price will roll over.
✗Don't assume your telehealth provider can run the Bridge paperwork (most can't — it's a special CMS process).
✗Don't assume compounded GLP-1s are a like-for-like swap. They are not the same as the FDA-approved versions.

When does the Medicare GLP-1 Bridge end, and why was it extended?

The Bridge starts July 1, 2026 and is scheduled to end December 31, 2027. It was originally going to end after just six months, in December 2026. CMS stretched it to 18 months because the long-term replacement program wasn’t ready — too few insurers signed on in time.

The original plan had two steps: a quick six-month Bridge, then a bigger, voluntary program called BALANCE, where CMS negotiates lower prices with the drugmakers and insurers choose whether to join. When the deadline came in spring 2026, too few Medicare drug plans agreed to take part. (NPR) So instead of letting coverage fall off a cliff in 2027, CMS kept the Bridge running an extra year and gave insurers more time to negotiate. (AHA)

Date	What happens
Dec. 23, 2025	CMS announces the BALANCE Model and the short-term Bridge (CMS)
April 2026	CMS delays the Medicare drug-plan part of BALANCE and extends the Bridge to Dec. 31, 2027 (AHA)
July 1, 2026	Bridge goes live nationwide, in every state and territory (CMS)
2026–2027	Eligible members get covered drugs for $50/month
Oct. 15 – Dec. 7, 2027	Medicare Open Enrollment — your window to check 2028 plans (Medicare.gov) Put this on your calendar now.
Dec. 31, 2027	Bridge scheduled to end
Jan. 1, 2028	Possible next phase — but not guaranteed

That October-to-December 2027 window matters more than people realize. It’s the one time of year you can change your Medicare drug plan, with changes that start January 1. If a 2028 coverage path appears, that’s when you grab it. Put it on the calendar now.

Will BALANCE automatically replace the Medicare GLP-1 Bridge?

No. BALANCE should be treated as a possible next step, not an automatic replacement. CMS describes the Medicare drug-plan version as a future goal that still needs insurers to opt in, and KFF says plainly that it’s uncertain how Bridge members will keep their obesity-drug coverage after 2027. (CMS, KFF)

BALANCE (it stands for “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth”) is a test program from CMS. The idea: CMS negotiates lower GLP-1 prices with the drugmakers, and the Medicaid programs and Medicare drug plans that choose to join pass those prices to patients, along with free lifestyle support. (CMS) The drugmakers — Eli Lilly and Novo Nordisk — have already agreed to take part. (CMS)

So the pieces are moving. But “the manufacturers agreed” is not the same as “your plan will cover it.” Two big question marks remain. First, will enough Medicare drug plans actually join? (That’s the exact thing that fell short the first time.) Second, even if BALANCE launches, plans could drop out before the program’s final year, and the underlying law still bans Medicare from covering weight-loss drugs unless something changes. (KFF)

Some pages imply a clean handoff: Bridge ends, BALANCE begins, you barely notice. We’re not going to tell you that, because it’s not confirmed. The honest version: a replacement may come, but it is not promised under the rules we have today. Plan for the gap. If BALANCE shows up, great — you lost nothing by being ready.

Want the full picture on the replacement program? CMS BALANCE Model GLP-1 Explained →

The single best way to keep coverage after the Bridge ends

Your most durable coverage isn’t the Bridge at all — it’s qualifying for a GLP-1 under a condition Medicare already covers. Medicare’s prescription coverage (Part D) can pay for these drugs when they treat type 2 diabetes, lower heart-attack and stroke risk in people with heart disease, or treat obstructive sleep apnea — and that path isn’t tied to the Bridge’s 2027 deadline. (CMS)

Medicare has a strange rule: by law, it can’t cover a drug used only for weight loss. That’s the whole reason the Bridge had to be created as a special workaround. But the same drug, prescribed for a different approved reason, runs through normal Medicare coverage — no Bridge, and no December 2027 expiration date hanging over it. (CMS)

Federal analysts estimated that about 73% of Medicare enrollees with obesity already have access to the GLP-1 they’re prescribed under Part D, based on the other diagnoses already in their records. (HHS ASPE) In plain English: there’s a real chance the door is already open for you. You just have to walk through it.

Here are the three doors.

Your condition	The drug	Approved use that unlocks coverage	What to ask your doctor
Obstructive sleep apnea (breathing stops and starts during sleep)	Zepbound	Moderate-to-severe sleep apnea in adults with obesity (FDA-approved Dec. 2024)	"Should I get a sleep study? Could Zepbound be covered for my sleep apnea?"
Heart disease	Wegovy	Lowering heart-attack and stroke risk in adults with known heart disease who are overweight or obese (FDA-approved March 2024)	"I've had heart issues — do I qualify under the cardiovascular approval?"
Type 2 diabetes	Ozempic, Mounjaro (and others)	Type 2 diabetes (long-covered by Part D)	"Which diabetes-covered GLP-1 on my plan fits me?"

A quick, honest note: this is more durable than the Bridge because it isn’t on the 2027 clock — but it isn’t a blank check. Your specific plan still has its own drug list (the “formulary”), prior-approval rules, and copays, and those can change year to year. The point is that the path stays open after the Bridge closes. That’s worth a lot.

Zepbound for obstructive sleep apnea

Sleep apnea is common in people carrying extra weight — and many people have it without ever being diagnosed. Zepbound earned FDA approval for moderate-to-severe sleep apnea in adults with obesity in December 2024, which created this Part D coverage path. (FDA) In the SURMOUNT-OSA study, Zepbound sharply reduced breathing disruptions, and a large share of participants improved enough that they no longer met the criteria for sleep apnea. If you snore heavily, wake up gasping, or feel exhausted despite a full night’s sleep, raise it with your doctor. A sleep study could change your whole coverage picture. (One thing to know: Wegovy is not approved for sleep apnea — Zepbound is the only GLP-1 with that approval.)

Wegovy for heart disease

If you’ve had a heart attack or stroke, or you have known heart disease, this path is built for you. The FDA approved Wegovy in March 2024 to lower the risk of heart attack, stroke, and cardiovascular death in adults who have established heart disease and are overweight or obese. (FDA) Because that’s a heart-disease use, not a weight-loss use, it isn’t blocked by Medicare’s weight-loss exclusion. The approval rests on the SELECT trial, which found Wegovy cut major cardiovascular events by about 20% in people with heart disease.

Type 2 diabetes (Ozempic, Mounjaro)

If you have type 2 diabetes, Medicare drug plans commonly cover GLP-1s like Ozempic and Mounjaro for that condition. These drugs were never on the Bridge — the Bridge is only for weight loss — so they run through standard diabetes coverage, which doesn’t expire in 2027. (CMS) One thing to keep straight: prediabetes can help you qualify for the Bridge at certain weight thresholds, but it is not the same as a type 2 diabetes coverage path.

Not sure which path fits your situation? Get your free personalized GLP-1 action plan →

Answer a few quick questions and get matched with your best next step. Free, no pressure.

What if your Part D plan denies GLP-1 coverage after the Bridge?

A first denial is not the end of the road. If your GLP-1 is prescribed for a Part D-coverable use, your doctor can request a formulary exception or file an appeal — and the Bridge does not change your normal Part D appeal rights. (CMS)

Your plan’s “formulary” is just its list of covered drugs. A formulary exception is a formal request asking your plan to cover a drug that isn’t on its list, or to cover it at a better price, because it’s medically necessary for you. Your doctor sends in the records that show why. (Medicare.gov)

If the plan still says no, Medicare gives you a defined appeals process with several levels, and you typically have a set number of days to move to the next step — so don’t sit on a denial letter. (Medicare.gov) The move is simple: get the qualifying diagnosis documented, ask your plan to cover the drug for that reason, and if you’re denied, appeal with your doctor’s help. People win these appeals when the paperwork is solid. Start before your $50 Bridge price runs out, not after.

Who is most at risk of a post-Bridge coverage cliff?

The highest-risk person is someone using the Bridge for weight loss alone, with no separate condition that Medicare already covers. People on fixed incomes, people whose drug or dose isn’t on the Bridge list, and caregivers managing a parent’s medicine should start planning early — but “at risk” does not mean “out of luck.” It means you have homework to do before late 2027.

Higher risk if:

·You qualify for the Bridge only through weight/BMI rules, with no diabetes, heart disease, or sleep apnea path.
·Your monthly budget is close to that $50 line.
·You take a drug or form that isn't on the Bridge (e.g., Zepbound vials instead of the KwikPen).
·You don't have a regular prescriber who can handle the paperwork.
·You're assuming BALANCE will automatically cover you in 2028.

You may have another path if:

·You take Ozempic, Mounjaro, or Rybelsus for type 2 diabetes.
·You take Wegovy and have known heart disease.
·You take Zepbound and have obstructive sleep apnea.
·Your plan allows a coverage exception or appeal.

About half of GLP-1 users say the drugs are hard to afford, and roughly a quarter call them “very difficult” to afford. (KFF) So if you’re anxious about a $50 price becoming a $350 price, you’re not overreacting. That jump is exactly what this page exists to help you avoid.

Which GLP-1 medications does the Medicare GLP-1 Bridge actually cover?

The Bridge covers three weight-loss drugs: Foundayo, Wegovy (shot and pill), and the Zepbound KwikPen. It does not cover Ozempic, Mounjaro, or Rybelsus for weight loss — those are diabetes drugs that may be covered through standard Medicare for diabetes instead. (CMS)

Medication	On the Bridge?	What to know
Foundayo (orforglipron, a pill)	✅ Yes	Newest option; FDA-approved April 1, 2026 (Lilly)
Wegovy shot (semaglutide)	✅ Yes	Covered for eligible weight-management use
Wegovy pill	✅ Yes	Covered for eligible weight-management use. Full Wegovy pill guide →
Zepbound KwikPen (tirzepatide)	✅ Yes	The KwikPen form specifically. Full Zepbound vials guide →
Zepbound single-dose vials	❌ No	Sold separately as cash-pay, not through the Bridge
Ozempic	❌ No (not for weight loss)	May be covered by your plan for type 2 diabetes
Mounjaro	❌ No (not for weight loss)	May be covered by your plan for type 2 diabetes
Rybelsus	❌ No (not for weight loss)	May be covered by your plan for type 2 diabetes

Who actually qualifies for the Bridge

To get the $50 Bridge price, a provider has to confirm you meet specific rules. You must be 18 or older, enrolled in a Medicare drug plan, and meet one of these health profiles — measured at the time you first started your GLP-1: (CMS)

1BMI of 35 or higher

2BMI of 30 or higher plus heart failure, uncontrolled high blood pressure, or chronic kidney disease (stage 3a or higher)

3BMI of 27 or higher plus prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease

The rules are checked based on your BMI when you started the drug — not your BMI today. (CMS) So if you began Zepbound two years ago at a BMI of 37, and the drug worked and you’re now at 34, you can still qualify. Your doctor just confirms you met the threshold when you started. Don’t let weight-loss success accidentally talk you out of coverage — make sure your records show your starting point.

For the full eligibility walkthrough: Medicare GLP-1 Bridge eligibility guide →

What does the $50 Medicare GLP-1 Bridge copay really mean?

The $50 is real, and it’s your full cost for that drug — but it comes with three catches that matter for planning. The Bridge runs outside normal Medicare drug coverage, the $50 doesn’t count toward your yearly out-of-pocket limit, and low-income help doesn’t reduce it. (CMS)

Catch #1: It doesn't count toward your out-of-pocket cap.

In 2026, Medicare caps what you pay out of pocket for covered drugs at $2,100 a year. (Medicare.gov) Normally, hitting that cap makes your other drugs cheaper. But your $50 Bridge payments don't count toward it. (CMS) So if you take other expensive medicines, the Bridge won't help you reach that cap faster.

Catch #2: Extra Help doesn't lower it.

If you get Medicare's "Extra Help" (the Low-Income Subsidy that cuts drug costs for people with limited income), that help does not apply to the Bridge. (CMS) This is the program's most painful gap: the people who most need a break still pay the full $50.

Catch #3: Coupons don't stack.

Manufacturer coupons and discount cards can't be combined with the Bridge price. (CMS)

None of this makes the Bridge a bad deal — $50 for a drug that lists for over $1,000 is excellent. It just means the Bridge is a temporary CMS program that runs outside normal Medicare drug coverage, not the same thing as permanent insurance. Which is exactly why your 2028 plan matters.

Deep dive: Medicare GLP-1 Bridge $50 copay — the full guide →

What if $50 is still too much, or you get Extra Help?

If $50 a month is a stretch, you are not alone, and there are still moves to make. The hard truth first: CMS says Extra Help (the Low-Income Subsidy) does not lower the $50 Bridge copay. (CMS) So the program’s discount doesn’t go further for low-income members the way it does for most other drugs.

If money is tight, here’s where to focus. First, the covered-condition path matters even more for you — if your GLP-1 can be covered under diabetes, heart disease, or sleep apnea, your normal Part D cost-sharing (often a smaller copay) may beat the flat $50, and it doesn’t expire in 2027. Ask your doctor about that route. Second, review your full drug plan during Open Enrollment each fall; the right plan can lower your overall costs. Third, ask each drugmaker directly whether you qualify for an income-based patient assistance program — these are separate from coupon cards, and eligibility varies, so it’s worth a phone call. The key is to start these conversations early, not in the last month before a price change.

What will you actually pay if Medicare won’t cover it?

If you don’t qualify under a covered condition and no replacement program reaches your plan, that $50 becomes real cash pricing — roughly $149 a month for the Foundayo pill, about $349 for Wegovy, and $299–$449 for Zepbound vials. None of these cash purchases count toward your Medicare deductible or out-of-pocket cap. (Lilly, NovoCare, Medicare.gov)

The Post-Bridge Cost Cliff (per month)

Path	What you’d pay	The catch
On the Bridge (through 12/31/2027)	$50 flat, any dose	Ends Dec. 31, 2027 (CMS)
Part D under a covered condition	Your plan's copay or coinsurance (often modest)	Depends on your plan and approval — but it isn't on the Bridge's clock (CMS)
Foundayo (pill) — direct or telehealth	$149 to start, up to $349 at the highest doses	Newer drug; the $25 price needs commercial insurance, which Medicare members can't use (Lilly)
Wegovy — NovoCare or TrumpRx	$349 standard pen; $399 for Wegovy HD; the pill starts at $149	Cash price; doesn't count toward Medicare costs (NovoCare)
Zepbound vials/KwikPen — LillyDirect	$299 / $399 / $449 by dose with on-time refills	Miss the 45-day refill window and higher doses run $499–$699 (Lilly)
Brand list price (no coverage, no program)	$1,000+	Zepbound lists about $1,086 — this is what these programs save you from (Lilly)

Sources: CMS; Lilly; NovoCare; Medicare.gov. Prices verified May 28, 2026 — confirm before relying on them.

Paying cash is a real fallback, but it’s several times the Bridge price. That’s why the covered-condition door — the one that isn’t on the Bridge’s clock — is worth so much effort, and why you want a backup lined up before you need it, not after.

Buying direct from the drugmakers — and what TrumpRx really is

You can buy Zepbound, Wegovy, and Foundayo straight from the makers at cash prices far below the list price — and for Medicare members, this is usually the most reliable cash route. Two details can cost you, though: the cheapest LillyDirect Zepbound prices require refilling within 45 days, and cash purchases don’t count toward your Medicare deductible or out-of-pocket maximum. (Lilly, Medicare.gov)

LillyDirect (for Zepbound)

·$299 for 2.5 mg, $399 for 5 mg, $449 for 7.5–15 mg — if you refill within 45 days.
·Miss the 45-day window: regular price applies — $499 for 7.5 mg and $699 for 10 mg and up.
·Set a calendar reminder around day 30.
·Lilly offers these self-pay prices regardless of insurance status. (Lilly)

NovoCare (for Wegovy)

·Standard self-pay pen: $349/month. Wegovy HD 7.2 mg: $399/month. Wegovy pill starting at $149.
·New patients: two lowest pen doses for $199/month for the first two fills, through June 30, 2026. (NovoCare)
·The "$25 a month" price needs commercial insurance — NOT available to people with Medicare. (NovoCare)

TrumpRx.gov

·Launched February 2026 — but it's a price-comparison portal, not a store.
·You can't buy drugs directly from TrumpRx — it points you to the makers' lowest cash prices, which you then buy through the manufacturer. (Medicare.gov)
·Cash purchases there don't count toward your Medicare costs. (Medicare.gov)

One rule for every Medicare member: because of federal anti-kickback law, manufacturer copay savings cards (the “$25” deals) aren’t available to you — not even if you offer to pay around your coverage. Paying the straight cash price is different, and as noted, Lilly allows that regardless of insurance status. If money is tight, ask each maker about income-based assistance programs.

Using telehealth to keep your FDA-approved GLP-1 after the Bridge

For your Medicare coverage question, telehealth is not the path. Ro states plainly that it can’t coordinate GLP-1 coverage for government insurance plans like Medicare. (Ro) Don’t count on a telehealth “coverage checker” to solve your Bridge or Part D coverage — that runs through your plan, your prescriber, and the CMS process.

Where telehealth can genuinely help: cash-pay convenience. If you’ve already decided to pay cash to stay on your FDA-approved brand, and you’d rather have a provider handle the prescription and home delivery than set up LillyDirect or NovoCare yourself, a service like Ro Body (sponsored affiliate link, opens in a new tab) bundles that. Ro says its cash medication prices match LillyDirect, NovoCare, and TrumpRx, and its Ro Body membership (sponsored affiliate link, opens in a new tab) is $39 the first month, then $149 a month, or as low as $74 a month if you prepay for a year (medication billed separately). (Ro)

Two honest things to weigh first. One: the membership is an extra cost on top of the drug, so if your only goal is the lowest price and you’re comfortable managing refills yourself, buying direct from Lilly or Novo is cheaper. Two — and this is the one Medicare members must check: Ro’s own pages disagree on whether you can join to pay cash if you have Medicare. Because Ro’s information is inconsistent, confirm your eligibility directly with Ro before you count on it.

Ro for Medicare members	The honest answer
Can Ro coordinate your Medicare coverage?	No — Ro says it can't coordinate GLP-1 coverage for government insurance plans like Medicare. (Ro)
Can you join to pay cash?	Maybe — Ro's own pages disagree on this, so confirm your eligibility with Ro directly. (Ro)
Cash medication price	Ro says it matches LillyDirect, NovoCare, and TrumpRx. (Ro)
Added cost	Ro Body membership: $39 first month, then $149/month, or as low as $74/month with annual prepay (medication billed separately). (Ro)
Does it run the Bridge paperwork?	Not verified — the Bridge uses a special CMS process, so handle that through your prescriber and plan.

Cash-pay options — not Medicare Bridge tools

Affiliate links. For readers paying cash — not for Medicare coverage or Bridge enrollment.

Compare FDA-approved options on Ro →See Sesame Care GLP-1 options →

For Medicare coverage itself, work with your plan, prescriber, and the CMS process.

Are compounded GLP-1s a safe fallback after Medicare coverage ends?

Compounded GLP-1s often look cheaper up front, but they should not be your default fallback — especially on Medicare. Compounded drugs are made-to-order by a pharmacy and are not FDA-approved, and the FDA has warned about unapproved GLP-1 products of unknown quality. (FDA) For most Medicare members, an FDA-approved brand with a clear cash price is the more straightforward, better-understood option.

We’ll never blur this line, because it matters for your safety and your trust in us. Compounded semaglutide or tirzepatide is not the same as Wegovy or Zepbound. It hasn’t gone through the FDA’s review for safety, quality, and consistency, while the brand-name medicines have. (FDA) That doesn’t make every compounded option dangerous, but it does make it a real risk-and-benefit conversation to have with a licensed clinician — not a casual swap to save money.

If you want the full picture on safety, legality, and cost first, we keep it in a dedicated guide. Ask your doctor about the risk-benefit tradeoff before considering a compounded option.

Will you regain the weight if you stop a GLP-1 after coverage ends?

Many people regain a significant amount of weight after stopping a GLP-1, which is why the coverage question is really a continuity-of-care question. In the STEP 1 extension study, people regained about two-thirds of their lost weight within a year of stopping semaglutide. (STEP 1 extension) In the SURMOUNT-4 trial, most people who stopped tirzepatide regained 25% or more of their lost weight within a year, and the heart-and-metabolism benefits faded too. (SURMOUNT-4, JAMA)

The flip side is encouraging: in SURMOUNT-4, roughly 9 in 10 people who stayed on tirzepatide kept at least 80% of their weight loss, compared with far fewer who stopped. (SURMOUNT-4) Staying on treatment is what protects the results. So a coverage gap isn’t just a budgeting problem — it’s a health problem. Build your bridge to 2028 before you reach the edge.

If you’re facing a possible stop, ask your doctor what a safe plan looks like for you — taper, switch, pause, or continue another way. That’s a clinical decision, and it should be made with your prescriber, not a website.

Should you switch medications before the Bridge ends?

Don’t switch GLP-1 medications just because a website suggests it. Switching should be a clinical decision based on your diagnosis, side effects, dose history, how well it’s working, and your coverage path — not a guess. A switch that makes sense on paper can backfire in your body.

That said, there are a few situations where it’s at least worth a conversation with your doctor:

·Your current drug or form isn't on the Bridge (for example, Zepbound vials instead of the KwikPen).

·Your condition might be covered through standard Medicare under a different approval (sleep apnea, heart disease, diabetes).

·A drug you could actually afford long-term has a cash option that fits your budget.

·You'd prefer a pill over a shot (Foundayo and the Wegovy pill are options to ask about).

·You're having side effects or have a safety concern.

A safety note worth reading: GLP-1s aren’t right for everyone. Wegovy and Zepbound carry warnings against use in people with a personal or family history of medullary thyroid cancer or a condition called MEN 2, plus other precautions. (FDA labeling) If you’re considering any change, make it with your prescriber — not on your own.

What should you ask your doctor before the Bridge ends?

Ask your doctor to document why you qualify, what your BMI was when you started, what diagnosis supports the medicine, and whether your drug could be covered through standard Medicare under a different approval. The most expensive mistake we see is waiting until the last refill to gather records — by then, your options have shrunk.

Your doctor-visit checklist

·Your current medication and dose
·The date you started GLP-1 therapy
·Your BMI when you started (this is the one that protects your Bridge eligibility)
·Your current BMI
·Any weight-related diagnoses
·A1C or prediabetes labs, if relevant
·Blood pressure history, if relevant
·Kidney labs (eGFR), if relevant
·Heart history — prior heart attack, stroke, or artery disease, if relevant
·A sleep apnea diagnosis or symptoms, if relevant
·Any prior-approval letters (approvals or denials)
·Your current Medicare drug plan name
·Your pharmacy's record of your fills

A simple script you can use:

“I’m trying to plan ahead for the Medicare GLP-1 Bridge ending after 2027. Can we document my starting BMI and the reason I’m on this medication — and check whether I have any separate, Medicare-covered reason to stay on a GLP-1 if the Bridge coverage changes?”

That one question can move you from the “Bridge-only, expires in 2027” group to the “covered condition, stays open” group. It’s the highest-value sentence on this entire page.

Get your free, personalized GLP-1 action plan →

Bring the checklist to your doctor — and if you'd like a plan matched to your situation, answer a few quick questions.

What should caregivers do for a parent on Medicare using GLP-1s?

Treat the Bridge end date like a benefits deadline, not just a medication question. The most useful things a caregiver can do are gather records, mark the key dates, and help the doctor and plan answer the right questions well before late 2027. A little organizing now prevents a scramble later.

Caregiver checklist

·Confirm the exact medication name and form.
·Confirm why it's prescribed — weight loss, diabetes, heart disease, sleep apnea, or something else. (This decides which coverage rules apply.)
·Keep the Medicare card, plan card, prescriber info, and pharmacy info together.
·Save any prior-approval letters.
·Ask whether the current provider can run the Bridge paperwork — and if not, who can.
·Put Medicare Open Enrollment (Oct. 15 – Dec. 7, 2027) on the calendar.
·Agree on a 'most we can afford per month' number, so a price change doesn't become a crisis.
·Ask the doctor what the plan is if the drug becomes unaffordable.

Your 2026, 2027, and 2028 plan

The best plan is not to wait until the Bridge ends. Use 2026 to confirm eligibility and document your records, 2027 to watch CMS and your plan, and late 2027 to lock in the best available 2028 path. Acting early is the whole game here.

When	What to do
Now	Confirm your drug, your reason for taking it, your starting BMI, and your prescriber path
Before July 1, 2026	Ask whether you qualify for the Bridge and what documentation you need
July 2026	If eligible, confirm how the Bridge claim and prior approval work for you
Each quarter, 2026–2027	Re-check CMS, your plan, and current prices
Summer 2027	Ask your doctor what your backup plan should be
Oct. 15 – Dec. 7, 2027	Compare plans; grab any 2028 coverage path during Open Enrollment
December 2027	Don't wait for your last refill to make a continuity plan
January 2028	Run your confirmed path — covered condition, appeal, cash-pay, or a clinical maintenance plan

What we actually verified

We believe a health page should show its work. Here’s exactly what we checked and where, as of May 28, 2026 — and what you should re-confirm yourself before making a decision, because this area changes fast.

Verified for this page (May 28, 2026)

✓Bridge start and scheduled end dates (CMS)
✓The $50 monthly price and that it's your total cost per drug (CMS)
✓The covered Bridge drugs, including the KwikPen detail (CMS)
✓That the $50 doesn't count toward your out-of-pocket cap (CMS)
✓That Extra Help doesn't lower the Bridge price (CMS)
✓Covered-condition uses (sleep apnea, heart disease, diabetes) aren't tied to the Bridge's end date (CMS)
✓That BALANCE's Medicare drug-plan launch was delayed and is not guaranteed (AHA, KFF)
✓Current cash prices from Lilly and NovoCare (Lilly, NovoCare)
✓Ro's stated pricing and Medicare limitations (Ro)
✓Medicare Open Enrollment dates and out-of-pocket cap (Medicare.gov)
✓Weight-regain findings from STEP 1 extension and SURMOUNT-4 (peer-reviewed)

Re-confirm before you decide

!Any new CMS update or further extension
!Whether BALANCE is announced for 2028
!Your specific plan's drug list and prior-approval rules
!Current manufacturer and telehealth prices (offers change)
!Your own eligibility to join any telehealth program as a Medicare member

Frequently asked questions

Is the Medicare GLP-1 Bridge ending in 2027?

Yes. Under current CMS rules, the Medicare GLP-1 Bridge is scheduled to end December 31, 2027. It could be extended or replaced, but neither is guaranteed today.

Will BALANCE replace the Bridge in 2028?

Maybe, but not automatically. CMS hopes to bring GLP-1 coverage into Medicare drug plans through BALANCE, but the Medicare piece was delayed and policy experts say 2028 coverage is uncertain.

Does the $50 Bridge copay count toward my Medicare out-of-pocket limit?

No. CMS says your Bridge cost-sharing doesn't count toward your yearly out-of-pocket total under Medicare drug coverage.

Does Extra Help lower the $50 Bridge copay?

No. The Low-Income Subsidy (Extra Help) does not reduce the Bridge price, so eligible low-income members still pay the full $50.

Can Medicare Advantage members use the Bridge?

Yes, if you're in a Medicare Advantage plan that includes drug coverage (an MA-PD plan) and you meet the Bridge's clinical rules. Standalone drug plans, Special Needs Plans, employer or union Medicare drug plans, and LI NET are also included; some plan types like PACE are not.

Are Ozempic and Mounjaro covered by the Bridge?

Not for weight loss — they're not on the Bridge drug list. They may be covered through your regular Medicare drug plan when prescribed for type 2 diabetes.

Is the Zepbound vial covered by the Bridge?

No. The Bridge covers the Zepbound KwikPen. The single-dose vials are sold separately as a cash-pay product.

Who submits the prior authorization for the Bridge?

Your doctor (or other provider) submits the prior-approval request and prescription to a central processor — not to your regular drug plan.

My BMI is lower now because the drug worked. Do I still qualify?

Likely yes. The Bridge checks your BMI from when you first started the drug, not today. Your doctor can confirm that you met the threshold at the start, even if you've since lost weight.

Can Ro help if the Bridge ends?

Ro can be useful for FDA-approved cash-pay options, but Ro says it currently can't help coordinate GLP-1 coverage for government insurance plans like Medicare, and its pages are inconsistent about whether Medicare members can join to pay cash. Confirm your eligibility with Ro directly, and handle Medicare coverage itself through your plan, prescriber, and the CMS process.

Are compounded GLP-1s the same as the FDA-approved drugs?

No. Compounded GLP-1s are not FDA-approved, and the FDA has warned about unapproved versions of unknown quality. They're a separate risk-benefit discussion to have with a licensed clinician.

The bottom line

When the Medicare GLP-1 Bridge ends on December 31, 2027, your $50 price isn’t guaranteed to continue — and the official replacement is still a maybe. But you are not stuck waiting and hoping. Your strongest, most durable move is to find out whether your GLP-1 qualifies under a condition Medicare already covers, because that path isn’t tied to the Bridge’s calendar. If it isn’t yours, you now know the real cash numbers and the most reliable way to keep your treatment going without a gap.

Don’t wait for your last refill. Take the next small step today.

Take our free 60-second matching quiz →

Answer a few quick questions and get a personalized plan matched to your situation and your best next step. Free, no pressure, built for you.

Related guides

Sources

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. The Medicare facts on this page come from CMS, Medicare.gov, the FDA, and peer-reviewed research, all linked above. Some telehealth links may earn us a commission. That never changes a price you pay, and it never changes the facts above. This page is information, not medical advice — your doctor and your plan make the final call. Last verified: May 28, 2026.